BaseFold is pushing the boundaries of drug discovery by using AI and diverse biological data to predict complex protein structures with unprecedented accuracy.
Emerging gene editing technologies including base editing, prime editing, ZFNs, and TALENs show promising therapeutic applications treating genetic diseases.
YolTech Sells China Rights to Cholesterol Gene Editing Therapy for $29 Million
Biotech firm YolTech has reached a significant agreement to sell the China rights to its innovative cholesterol-lowering gene editing therapy to Salubris, a leading Chinese pharmaceutical company, for $29 million.
Merck Group’s Strategic Acquisition of Eyebio Enhances Ophthalmology Portfolio
$3 billion deal: Merck has announced the acquisition of Eyebio, a cutting-edge biotechnology company specializing in innovative treatments for eye diseases.
